Production of leukocyte migration inhibition factor by lymphocytes of larynx cancer patients stimulated by laryngeal carcinoma solubilized membrane antigens. 1982

G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine

The production of leukocyte migration inhibition factor (LIF) from lymphocytes after stimulation with 3 M KCl soluble tumor and normal mucosa extracts was investigated in 30 patients with laryngeal carcinoma at different development stages and in 30 normal donors. The experiments were performed in heterologous and autologous systems. In heterologous systems 3 M KCl tumor extracts induced LIF production by heterologous lymphocytes from patients in 91% of the cases, and normal mucosa extracts induced LIF production by heterologous lymphocytes from patients in 73% of the cases and from normal donors in 90% of the cases. In autologous systems 3 M KCl tumor extracts induced LIF production by autologous lymphocytes from the same patients in 65% of the cases, whereas the normal laryngeal mucosa extracts induced LIF production by the same autologous lymphocytes in the 6% of the cases. The high positivity percentage of the test in heterologous systems could be related to differences in the major histocompatibility complex. The 65% test positivity in autologous systems using tumor extracts could be related to the presence of tumor associated antigens.

UI MeSH Term Description Entries
D007822 Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. Cancer of Larynx,Laryngeal Cancer,Larynx Neoplasms,Cancer of the Larynx,Larynx Cancer,Neoplasms, Laryngeal,Cancer, Laryngeal,Cancer, Larynx,Cancers, Laryngeal,Cancers, Larynx,Laryngeal Cancers,Laryngeal Neoplasm,Larynx Cancers,Larynx Neoplasm,Neoplasm, Laryngeal,Neoplasm, Larynx,Neoplasms, Larynx
D007830 Larynx A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE. Anterior Commissure, Laryngeal,Anterior Commissure, Larynx,Laryngeal Anterior Commissure,Laryngeal Posterior Commissure,Posterior Commissure, Laryngeal,Posterior Commissure, Larynx,Anterior Commissures, Laryngeal,Anterior Commissures, Larynx,Commissure, Laryngeal Anterior,Commissure, Laryngeal Posterior,Commissure, Larynx Anterior,Commissure, Larynx Posterior,Commissures, Laryngeal Anterior,Commissures, Laryngeal Posterior,Commissures, Larynx Anterior,Commissures, Larynx Posterior,Laryngeal Anterior Commissures,Laryngeal Posterior Commissures,Larynx Anterior Commissure,Larynx Anterior Commissures,Larynx Posterior Commissure,Larynx Posterior Commissures,Posterior Commissures, Laryngeal,Posterior Commissures, Larynx
D007961 Leukocyte Migration-Inhibitory Factors Protein factor(s) released by sensitized lymphocytes (and possibly other cells) that inhibit the movement of LEUKOCYTES, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the LEUKOCYTE MIGRATION CAPILLARY TUBE TECHNIQUE (LMCT) and the LEUKOCYTE MIGRATION AGAROSE TEST (LMAT). Migration-Inhibition Factors, Leukocyte,Leukocyte Migration-Inhibition Factors,Migration-Inhibitory Factors, Leukocyte,Factors, Leukocyte Migration-Inhibition,Factors, Leukocyte Migration-Inhibitory,Leukocyte Migration Inhibition Factors,Leukocyte Migration Inhibitory Factors,Migration Inhibition Factors, Leukocyte,Migration Inhibitory Factors, Leukocyte
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D002464 Cell Migration Inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated LEUKOCYTES or MACROPHAGES. Specific CELL MIGRATION ASSAYS have been developed to estimate levels of migration inhibitory factors, immune reactivity against tumor-associated antigens, and immunosuppressive effects of infectious microorganisms. Chemotaxis Inhibition,Chemotaxis Inhibitions,Inhibition, Chemotaxis,Inhibitions, Chemotaxis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor

Related Publications

G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
March 1977, Bollettino dell'Istituto sieroterapico milanese,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
November 1976, International journal of cancer,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
August 1976, Bollettino della Societa italiana di biologia sperimentale,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
February 1981, Clinical immunology and immunopathology,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
September 1976, International journal of cancer,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
January 1976, Bollettino dell'Istituto sieroterapico milanese,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
January 1979, Biochimica et biophysica acta,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
May 1981, The American journal of clinical nutrition,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
January 1984, Archiv fur Geschwulstforschung,
G Cortesina, and G P Cavallo, and F Beatrice, and A Sartoris, and M Bussi, and B Morra, and V Di Fortunato, and E Poggio, and S Rendine
February 1981, Clinical immunology and immunopathology,
Copied contents to your clipboard!